General Assembly
The General Assembly consists of representatives from all partners in the project, both from academia, research institutes, SMEs and EFPIA companies. The General Assembly meets once a year for an annual project meeting. It is responsible for project-level decisions of strategic and financial importance, whereas the regular oversight of the project is done by the Steering Committee.
Strategic bodies
Steering Committee
The PrIMAVeRa Steering Committee is responsible for overseeing the execution of the work plan, alignment across the different WPs, interactions with the COMBINE project and decision making regarding scientific and technical aspects.
Composition:​
​
Project Coordinator and Chair of SC: Ole Olesen, European Vaccine Initiative (EVI)
Scientific coordinator: Marc Bonten, University Medical Center Utrecht (UMCU)
Industry Leader: Venanzio Vella, GlaxoSmithKline (GSK).
​
​
Work package Academic Leaders & Industry Co-leaders:
​
WP1
Academic Lead: Stephan Harbarth and Marlieke de Kraker, University of Geneva (UNIGE)
Industry Co-Lead: Venanzio Vella, GlaxoSmithKline (GSK)
​
WP2
Academic Lead: Frank Aarestrup and Tine Hald, Technical University of Denmark (DTU)
Industry Co-Lead: Andrea Palladino, GlaxoSmithKline (GSK)
​
WP3
Academic Lead: Jesús Rodríguez Baño, Servicio Andaluz de Salud (SAS)​
Industry Co-Lead: Maureen P. Neary, Janssen Vaccines & Prevention (Janssen)
​
WP4
Academic Lead: Martin Bootsma, University Medical Center Utrecht (UMCU)
Industry Co-Lead: Raymond A. Farkouh, Pfizer (Pfizer)
​
WP5
Academic Lead: Michael McConnell, Institute of Health Carlos III (ISCIII)
Industry Co-Lead: Lorenzo Argante, GlaxoSmithKline (GSK)
​
WP6
Academic Lead: Irina Meln, European Vaccine Initiative (EVI)
Industry Co-Lead: Jeanne Egar, GlaxoSmithKline (GSK)
​
WP7
Academic Lead: Irina Meln, European Vaccine Initiative (EVI)
Industry Co-Lead: Jeanne Egar, GlaxoSmithKline (GSK)
​
WP8
Academic Lead: Irina Meln, European Vaccine Initiative (EVI)
Industry Co-Lead: Jeanne Egar, GlaxoSmithKline (GSK)
​
​